The Technical Analyst
Viking Therapeutics Inc [VKTX]
Exchange: NASDAQ Capital Market Sector: Healthcare Industry: Biotechnology
Viking Therapeutics Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: BUY (auto-tracking)
3.86% $2.42
Last updated: 16 May 2022 @ 12:07 pm
FIND ALL MARKETS
FIND ALL STOCKS LISTED @ NASDAQ Live Signal Oslo
Live Signal Nasdaq
Live Signal Crypto
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 187.24 mill |
| EPS: | -0.733 |
| P/E: | 0.000 |
| Earnings Date: | Jul 26, 2022 |
| SharesOutstanding: | 77.37 mill |
| Avg Daily Volume: | 0.975 mill |
| RATING 2022-05-13 |
|---|
| B+ |
| Buy |
| RATINGDETAILS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Neutral | |
| Return On Asset: | Neutral | |
| DE: | Neutral | |
| P/E: | Strong Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 4/20 | 1/21 | 2/21 | 3/21 | 4/21 | 1/22 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | |
| Gr.Profit | n/a | n/a | n/a | n/a | n/a | |
| Ebit | ||||||
| Asset | ||||||
| Debt |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$2.78 (15.01%) $0.363 |
| Date: 2022-05-16 |
| True Range Average |
|---|
|
+/- $0.166 ( +/- 7.12%) Range: 2.16 - 2.50 |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2022-05-02 | Foehr Matthew W | Buy | 45 000 | Common Stock, par value $0.00001 per share |
| 2022-01-15 | Mancini Marianna | Sell | 827 | Common Stock, par value $0.00001 per share |
| 2022-01-04 | Lian Brian | Sell | 390 000 | Stock Option (Right to Buy) |
| 2022-01-04 | Lian Brian | Sell | 26 432 | Common Stock, par value $0.00001 per share |
| 2022-01-04 | Mancini Marianna | Sell | 174 000 | Stock Option (Right to Buy) |
| INSIDER POWER |
|---|
| 5.47 |
| Last 100 transactions |
| Buy: 3 131 616 | Sell: 3 376 644 |
Forecast:
13:46 - $2.43
Live Trading Signals (every 1 min)
Forecast
1: 12:16 - $2.43
Forecast 2: 13:06 - $2.44
Forecast 3: 13:46 - $2.43
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $2.42 (3.86% ) |
| Volume | 0.338 mill |
| Avg. Vol. | 0.975 mill |
| % of Avg. Vol | 34.64 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For VKTX
186 Signals | Accuracy: 22.04% | Accuracy Buy: 22.58% | Accuracy Sell: 21.51%
Avg return buy: -0.07 % | Avg return sell: 0.04 %
$1 invested is now $0.93 or -7.04% since 20-04-22
| Date | Signal | @ | Closed | % | May 16 - 11:13 | buy | $2.39 | $2.42 @ May 16 - 12:01 | 1.05% |
|---|---|---|---|---|
| May 16 - 11:02 | sell | $2.38 | $2.39 @ May 16 - 11:12 | 0.18% |
| May 16 - 10:22 | buy | $2.34 | $2.38 @ May 16 - 10:54 | 1.50% |
| May 16 - 09:48 | sell | $2.33 | $2.34 @ May 16 - 10:21 | 0.65% |
| May 16 - 09:44 | buy | $2.33 | $2.31 @ May 16 - 09:47 | -0.86% |
| May 16 - 09:42 | sell | $2.33 | $2.33 @ May 16 - 09:43 | 0.22% |
| May 16 - 09:38 | buy | $2.33 | $2.33 @ May 16 - 09:41 | -0.21% |
| May 13 - 16:42 | sell | $2.33 | $2.33 @ May 16 - 09:38 | 0.00% |
| May 13 - 15:55 | buy | $2.33 | $2.33 @ May 13 - 16:41 | 0.22% |
| May 13 - 15:51 | sell | $2.31 | $2.32 @ May 13 - 15:53 | 0.43% |
VKTX
Latest Press Releases
2022-04-27 16:08:00 - Press Release
Viking Therapeutics Reports First Quarter 2022 Financial Results And Provides Corporate Update
Conference call scheduled for 4:30 p.m. et today completion of enrollment in phase 2b voyage study of vk2809 in biopsy-confirmed nash expected in 2h22 phase 1 study of dual glp-1/gip agonist vk2735 ongoing; results expected by year-end quarter-end cash balance of $185m provides runway through multiple clinical catalysts san diego , april 27, 2022 /prnewswire/ -- viking therapeutics, inc. (viking) (nasdaq: vktx), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the first quarter ended march 31, 2022, and provided an update on its clinical pipeline and other corporate developments.
2022-02-02 20:56:00 - Press Release
Shareholder Alert: Pomerantz Law Firm Investigates Claims On Behalf Of Investors Of Viking Therapeutics, Inc. - Vktx
New york, new york--(newsfile corp. - february 2, 2022) - pomerantz llp is investigating claims on behalf of investors of viking therapeutics, inc. ("viking" or the "company") (nasdaq: vktx). such investors are advised to contact robert s. willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.the investigation concerns whether viking and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [click here for information about joining...
2022-01-27 18:55:00 - Press Release
Shareholder Alert: Pomerantz Law Firm Investigates Claims On Behalf Of Investors Of Viking Therapeutics, Inc. - Vktx
New york, jan. 27, 2022 /prnewswire/ -- pomerantz llp is investigating claims on behalf of investors of viking therapeutics, inc. ("viking" or the "company") (nasdaq: vktx). such investors are advised to contact robert s.
2022-01-24 07:02:00 - Press Release
Viking Therapeutics Announces Clinical Hold On Phase 1b Trial Of Vk0214 In Patients With X-ald
San diego , jan. 24, 2022 /prnewswire/ -- viking therapeutics, inc. (viking) (nasdaq: vktx), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that its phase 1b clinical trial of vk0214 in patients with x-linked adrenoleukodystrophy (x-ald) has been placed on clinical hold by the united states food and drug administration (fda). the fda has requested an additional preclinical study prior to continuing the phase 1b study of vk0214 in x-ald.
2022-01-10 07:02:00 - Press Release
Viking Therapeutics Announces Initiation Of Phase 1 Clinical Trial Of Vk2735, Company's Lead Dual Glp-1/gip Receptor Agonist
San diego, jan. 10, 2022 /prnewswire/ -- viking therapeutics, inc. (viking) (nasdaq: vktx), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the initiation of a phase 1 single ascending dose (sad) and multiple ascending dose (mad) clinical trial of vk2735, a novel dual agonist of the glucagon-like peptide 1 (glp-1) and glucose-dependent insulinotropic polypeptide (gip) receptors. vk2735 is in development for the potential treatment of various metabolic disorders.
Latest News
2022-04-27 22:49:08 - Seeking Alpha
Viking Therapeutics' (VKTX) CEO Brian Lian on Q1 2022 Results - Earnings Call
Viking Therapeutics, Inc. (NASDAQ:VKTX ) Q1 2022 Earnings Conference Call April 27, 2022 4:30 PM ET Company Participants Stephanie Diaz – Manager-Investor Relations Brian Lian – President and Chief Executive Officer Greg Zante – Chief Financial Officer Conference Call Participants Jay Olson – Oppenheimer Steven Seedhouse – Raymond James Joe Pantginis – H.C. Wainwright Scott Henry – ROTH Capital Yale Jen – Laidlaw & Company Andy Hsieh – William Blair Justin Zelin – BTIG Operator Good day and welcome to the Viking Therapeutics 2022 First Quarter Financial Results Conference Call.
2022-04-06 16:05:00 - PRNewsWire
Viking Therapeutics to Present at the 21st Annual Needham Virtual Healthcare Conference
SAN DIEGO , April 6, 2022 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that its chief executive officer, Brian Lian, Ph.D., will deliver a corporate presentation as part of the 21st Annual Needham Virtual Healthcare Conference.
2022-02-10 15:36:00 - The Motley Fool
3 Biotech Stocks That Are too Cheap to Ignore
2022-02-09 21:29:10 - Seeking Alpha
Viking Therapeutics, Inc. (VKTX) CEO Brian Lian on Q4 2021 Results - Earnings Call
2022-01-26 10:45:19 - Zacks Investment Research
Viking (VKTX) Study on X-ALD Put on Clinical Hold by the FDA
2022-01-24 18:42:00 - The Motley Fool
Why Viking Therapeutics Stock Got Mashed on Monday
The clinical trial has been halted by the FDA for now, pending the submittal of a preclinical study.
2022-01-24 11:53:31 - Pulse2
Viking Therapeutics Stock (VKTX): Why The Price Substantially Went Down Today
The stock price of Viking Therapeutics Inc (NASDAQ: VKTX) fell by over 14% during intraday trading today. This is why it happened.
2022-01-24 07:33:27 - Benzinga
Viking Therapeutics' Early Stage Trial On FDA Hold In Rare Metabolic Disorder
The FDA has placed a clinical hold on Viking Therapeutics Inc's (NASDAQ: VKTX) Phase 1b trial of VK0214 in patients with X-linked adrenoleukodystrophy (X-ALD). The FDA has requested an additional preclinical study before continuing the Phase 1b study of VK0214 in X-ALD, not due to any findings from ongoing or previously completed studies.
2022-01-04 07:15:40 - 24/7 Wall Street
5 Sizzling ‘Strong Buy' Analyst Biotechnology Picks for 2022
For years, one of the most dependable sectors, especially for investors who are more conservative, was health care.
2022-01-03 07:30:00 - PRNewsWire
Viking Therapeutics to Present at H.C. Wainwright BioConnect 2022 Conference
SAN DIEGO, Jan. 3, 2022 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that its chief executive officer, Brian Lian, Ph.D., will deliver a corporate presentation as part of the H.C.